CAR-T Immuno-OncologyCAR-T肿瘤免疫疗法

Home / Products产品 / CAR-T Immuno-OncologyCAR-T肿瘤免疫疗法

Indication: Various Cancers

Technology Platform: Chimeric Antigen Receptor T cell (CAR-T) therapy CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors.

The Company has acquired Chinese PLA General Hospital’s (“PLAGH”, Beijing, also known as “301 Hospital”) Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) Immuno-Oncology patents (all pending), and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge. VIEW PRESS RELEASE HERE

CAR-T TherapyIndication
CD19Acute B lymphocytic leukemia
CD20Progressive malignant lymphoma
CD30Hodgkin’s lymphoma
EGFR (HER1)Advanced lung cancer
技术平台: 嵌合抗原受体T细胞(CAR-T)治疗技术


公司与中国人民解放军总医院(也称301医院)合作开发嵌合抗原受体T细胞(CAR-T)治疗技术,融合重组表达载体CD19,CD20,CD30和人体表皮生长因子受体(EGFR或HER1)肿瘤免疫患者(全部待定),以及上述技术的I/II期阶段临床数据与生产技术。VIEW PRESS RELEASE HERE

CAR-T 治疗技术
EGFR (HER1)晚期肺癌